Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial

Summary Background Autologous haemopoietic stem-cell transplantation (HSCT) improves survival in patients with multiple myeloma, but disease progression remains an issue. Allogeneic HSCT might reduce disease progression, but can be associated with high treatment-related mortality. Thus, we aimed to...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2011-12, Vol.12 (13), p.1195-1203
Hauptverfasser:	Krishnan, Amrita, MD, Pasquini, Marcelo C, MD, Logan, Brent, PhD, Stadtmauer, Edward A, Prof, Vesole, David H, Prof, Alyea, Edwin, MD, Antin, Joseph H, Prof, Comenzo, Raymond, Prof, Goodman, Stacey, Prof, Hari, Parameswaran, MD, Laport, Ginna, MD, Qazilbash, Muzaffar H, MD, Rowley, Scott, Prof, Sahebi, Firoozeh, MD, Somlo, George, MD, Vogl, Dan T, MD, Weisdorf, Daniel, Prof, Ewell, Marian, ScD, Wu, Juan, MS, Geller, Nancy L, PhD, Horowitz, Mary M, MD, Giralt, Sergio, Prof, Maloney, David G, Prof
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Chemotherapy Dexamethasone - administration & dosage Disease-Free Survival Female Graft vs Tumor Effect Hematology, Oncology and Palliative Medicine Hematopoietic Stem Cell Transplantation - adverse effects Hematopoietic Stem Cell Transplantation - mortality Humans Kaplan-Meier Estimate Male Middle Aged Mortality Multiple myeloma Multiple Myeloma - diagnosis Multiple Myeloma - drug therapy Multiple Myeloma - mortality Multiple Myeloma - surgery Myeloablative Agonists - therapeutic use Proportional Hazards Models Risk Assessment Risk Factors Survival Rate Thalidomide - administration & dosage Time Factors Transplantation, Autologous Transplantation, Homologous Transplants & implants Treatment Outcome United States Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Summary Background Autologous haemopoietic stem-cell transplantation (HSCT) improves survival in patients with multiple myeloma, but disease progression remains an issue. Allogeneic HSCT might reduce disease progression, but can be associated with high treatment-related mortality. Thus, we aimed to assess effectiveness of allogeneic HSCT with non-myeloablative conditioning after autologous HSCT compared with tandem autologous HSCT. Methods In our phase 3 biological assignment trial, we enrolled patients with multiple myeloma attending 37 transplant centres in the USA. Patients (
ISSN:	1470-2045 1474-5488
DOI:	10.1016/S1470-2045(11)70243-1